Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: video (4)

Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper.
press releaseinvestorvideoscienceARCHIVEkorman
ARCHIVE: GEN Biotechnology cover story: Bringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025
ARCHIVE: Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler Korman
investorpress clippingsvideoscienceARCHIVEkorman
ARCHIVE: Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler KormanApril 15, 2025
ARCHIVE: eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO
talentpress releaseinvestorvideoARCHIVEperriman
ARCHIVE: eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025
ARCHIVE: Fox Business: Interview with Chief Market Strategist, Lou Basenese
investorpress clippingsvideoARCHIVE
ARCHIVE: Fox Business: Interview with Chief Market Strategist, Lou BaseneseMarch 17, 2025
ARCHIVE: Fox Business: Interview with CEO Michael Heltzen
heltzeninvestorpress clippingsvideoARCHIVE
ARCHIVE: Fox Business: Interview with CEO Michael HeltzenMarch 3, 2025
ARCHIVE: Watch eXoZymes' Nasdaq closing bell ceremony
heltzeninvestorvideoARCHIVE
ARCHIVE: Watch eXoZymes' Nasdaq closing bell ceremonyFebruary 20, 2025
ARCHIVE: Creating value for partners through exozyme biosolutions
investorvideo
ARCHIVE: Creating value for partners through exozyme biosolutionsFebruary 12, 2025
ARCHIVE: The difference between enzymes and exozymes: Explaining our tech
investorvideoARCHIVE
ARCHIVE: The difference between enzymes and exozymes: Explaining our techFebruary 12, 2025
ARCHIVE: Vision: What's the potential impact of exozymes?
investorvideoARCHIVE
ARCHIVE: Vision: What's the potential impact of exozymes?February 12, 2025
ARCHIVE: eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymes
investorvideoARCHIVE
ARCHIVE: eXoZymes signifiy a sustainable paradigm shift in chemical production leveraging AI-engineered enzymesFebruary 12, 2025
Previous page
Page 4 of 5
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark